DE-CSC
9.10.2019 14:02:11 CEST | Business Wire | Press release
CSC announces a new domain name security intelligence API that can now bring together the power of CSC’s domain name security intelligence with other cloud-based security operations platforms. Debuting today at the FireEye Cyber Defense Summit 2019, this new solution will help the world's leading security experts, government leaders, and executives from various industries address important challenges in today’s cyber threat landscape, including the vulnerability of digital assets like domains, domain name systems (DNS), and digital certificates outside the firewall, noted by both companies as serious security blind spots.
Cyber threats such as domain name and DNS hijacking events enable criminals to redirect web traffic, email, apps, and other connections to services that rely on the hijacked domain name. The exploitation of weaknesses in DNS infrastructure is caused by a lack of controls, processes, and policies with most organizations. For clients leveraging a security operations platform or a SIEM, it’s now possible to display all your security intelligence in one place, adding security controls for domains, DNS, and digital certificates. This insight can help organizations mitigate the disruption of business continuity, leading to financial repercussions, loss of consumer trust, and sensitive data leaks. This is the first time any organization is able to integrate security controls for digital assets outside the firewall into their security operations platform including a SIEM.
“Customers today have vendor fatigue and are overwhelmed by managing multiple, disparate security solutions. With the CSC API accessible, our mutual customers will be able to monitor a suite of security events that occur outside their company’s firewall when integrated with the FireEye Helix Security Platform,” says Sean Morton, vice president of Customer Experience at FireEye. “Detecting risks such as DNS and domain name hijacking removes a significant blind spot in a company’s security strategy, providing valuable intelligence and alerts inside our security operations platform, ultimately increasing the efficiency and incident response times dealing with cyber threats.”
“As the world’s leading corporate domain name registrar, CSC is the only company in the unique position to provide visibility into the cyber risks associated with your business-critical digital assets outside the firewall—domains, DNS, and digital certificates. Coupled with other security operations platforms like FireEye Helix, our joint customers have access to a next generation security platform,” says Mark Calandra, senior vice president, CSC Digital Brand Services. “In response to the risk of DNS hijacking and other cyber crime noted in the Department of Homeland Security’s emergency directive and the UK National Cyber Security Centre’s security advisory , CSC’s advanced proprietary algorithms are designed to expose these blind spots that are a critical component for enhancing the security posture of any company with an online presence.”
The Cyber Defense Summit is being hosted by FireEye, and the conference takes place October 9-10, 2019, in Washington, D.C. CSC representatives will be in the exhibition hall to discuss CSC’s new Domain Name Security Intelligence API and its integration with FireEye Helix. We will also be discussing our recent Cyber Security Report highlighting the domain name security posture of global government defense contractors.
About CSC
CSC supports companies that are making significant investments in their security posture by exposing blind spots that exist within fundamental internet assets such as domain names, DNS, and digital certificates. By leveraging our proprietary security solutions, CSC secures companies from cyber threats to their digital assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties as a result of policies like GDPR. Along with internet assets, CSC protects online brands that are being exploited via counterfeit websites, fraud, and IP violations, and helps monitor and mitigate this, providing enforcement and advisory services to protect many of the world’s largest brands. Learn more at cscdigitalbrand.services .
About FireEye, Inc.
FireEye is the intelligence-led security company. Working as a seamless, scalable extension of customer security operations, FireEye offers a single platform that blends innovative security technologies, nation-state grade threat intelligence, and world-renowned Mandiant® consulting. With this approach, FireEye eliminates the complexity and burden of cyber security for organizations struggling to prepare for, prevent, and respond to cyber-attacks. FireEye has over 8,200 customers across 103 countries, including more than 50 percent of the Forbes Global 2000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005016/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
